



August 14, 2017

The General Manager  
Department of Corporate Services - CRD  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

**Sub : UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>th</sup> JUNE 2017 AND LIMITED REVIEW REPORT OF THE AUDITORS OF THE COMPANY IN RESPECT OF QUARTER ENDED 30<sup>TH</sup> JUNE 2017.**

Dear Sir,

We are enclosing hereto the Un-audited Financial Results in respect of the quarter ended 30<sup>TH</sup> June 2017 along with the Limited Review Report of the Auditors of the Company which has been adopted by the Board of Directors at their meeting held on August 14, 2017.

Kindly take the above on record and acknowledge the receipt

Thanking you

Yours Sincerely  
For TRANSGENE BIOTEK LIMITED

K KOTESWARA RAO  
CHAIRMAN & MANAGING DIRECTOR

Encls: as above

**TRANSGENE BIOTEK LIMITED**  
**68,69,&70, ANRICH INDUSTRIAL AREA**  
**BOLLARAM, MEDAK DISTRICT**

**STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 30.06.2017**

(Rs. In Lakhs)

Particulars	Quarter ended 30.06.2017	Quarter ended 31.03.2017	Quarter ended 30.06.2016	Previous Year ended 31.03.2017
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>1. Income from Operations</b>				
(a) Net Sales/Income from Operations (Net of excise duty)	-	8.84	2.15	32.49
(b) Other Operating Income	0.54	-	1.76	-
<b>Total income from Operations (net)</b>	0.54	8.84	3.91	32.49
<b>2. Expenses</b>				
(a) Cost of Materials consumed				
(b) Purchase of stock-in-trade				
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade				
(d) Employee benefits expense	8.05	11.54	14.62	54.98
(e) Depreciation and amortisation expense	247.37	247.37	502.00	1,752.71
(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	5.50	192.80	11.70	231.49
<b>Total Expenses</b>	260.91	451.71	528.32	2,039.18
<b>3. Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	-260.37	-442.86	-524.41	-2,006.69
4. Other Income	-	43.98	-	43.98
<b>5. Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)</b>	-260.37	-398.88	-524.41	-1,962.71
6. Finance Costs	0.00	0.00	0.02	0.08
<b>7. Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)</b>	-260.38	-398.88	-524.43	-1,962.79
8. Exceptional Items	-	-	-	-
<b>9. Profit / (Loss) from ordinary activities before tax (7 + 8)</b>	-260.38	-398.88	-524.43	-1,962.79
10. Tax expense	-	-	-	-
<b>11. Net Profit / (Loss) from ordinary activities after tax (9 + 10)</b>	-260.38	-398.88	-524.43	-1,962.79
12. Extraordinary items (net of tax expense _____ Lakhs)	-	-	-	-
<b>13. Net Profit / (Loss) for the period (11 + 12)</b>	-260.38	-398.88	-524.43	-1,962.79
14. Share of Profit / (loss) of associates *	-	-	-	-
15. Minority Interest*	-	-	-	-
<b>16. Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *</b>	-260.38	-398.88	-524.43	-1,962.79
17. Paid-up equity share capital (Face Value of the Share shall be indicated)	7,577.00	7,577.00	7,577.00	7,577.00





18. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-3,424.71	-3,424.71	7,888.89	-3,424.71
<b>19.i Earnings Per Share (before extraordinary items)</b> (of ` ____/- each) (not annualised):				
(a) Basic	-0.03	-0.05	-0.07	-0.26
(b) Diluted	-0.03	-0.05	-0.07	-0.26
<b>19.ii Earnings Per Share (after extraordinary items)</b> (of ` ____/- each) (not annualised):				
(a) Basic	-0.03	-0.05	-0.07	-0.26
(b) Diluted	-0.03	-0.05	-0.07	-0.26
See accompanying note to the Financial Results				

#### Notes to the Results


- 1) Work on oral delivery of insulin analogue belonging to the client has been completed and delivered to the party. We now wait for outcome of the ongoing studies at third party before proceeding to the next crucial step.
- 2) The sale of unused assets which are superfluous to the needs of the company has been completed. This facilitates the management to concentrate on the ongoing projects.
- 3) The loan from Union Bank of India has been paid fully from the sale proceeds of some of the assets of the company as mentioned above.
- 4) Work on some APIs is progressing on expected lines to bring their quality to European and US FDA compliance requirements.
- 5) No. of Investor complaints pending at the beginning of the quarter - 1; received same complaint during the quarter - 1; resolved during the quarter - 1.
- 6) The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 14th August 2017.

Place: Hyderabad

Date: 14/08/2017



For TRANSGENE BIOTEK LTD

  
Managing Director



## ANNEXURE IX TO CLAUSE 41

(Rs. In Lacs)

Standalone Statement of Assets and Liabilities		As at Period ended 30th June 2017	As at Year ended 31st Mar 2017
		(Audited)	(Audited)
<b>A EQUITY AND LIABILITIES</b>			
1	Share Holders Fund		
	(a) Share Capital	7,577.00	7,577.00
	(b) Reserves and Surplus	(3,685.09)	(3,424.71)
	(c) Money Received against Share Warrents	-	-
	<b>Sub Total - Share Holders' Fund</b>	<b>3,891.91</b>	<b>4,152.29</b>
2	Share Application Money pending allotment	-	-
3	Minority Interest	-	-
4	Non-Current Liabilities		
	(a) Long Term Borrowings	633.84	633.84
	(b) Deferred Tax Liabilities (Net)	-	-
	(c) Other Long-Term Liabilities	-	-
	(d) Long-term Provisions	12,087.86	12,087.86
	<b>Sub-Total- Non Current Liabilities</b>	<b>12,721.70</b>	<b>12,721.70</b>
5	Current Liabilities		
	(a) Short Term Borrowings	908.62	916.72
	(b) Trade Payables	54.45	55.97
	(c) Other Current Liabilities	212.21	190.57
	(d) Short-term Provisions	-	-
	<b>Sub-Total- Current Liabilities</b>	<b>1,175.28</b>	<b>1,163.26</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>17,788.90</b>	<b>18,037.25</b>
<b>B ASSETS</b>			
1	Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible assets	308.91	313.85
	(ii) Intangible assets	5,560.09	5,802.52
	(iii) Capital work-in-progress	28.90	28.90
	(b) Non- Current Investments	9,220.10	9,220.10
	(c) Deferred Tax Assets (Net)	-	-
	(d) Long-term Loans and Advances	2,420.87	2,420.87
	(e) Other Non Current Assets	174.77	174.77
	<b>Sub - total -Non Current Assets</b>	<b>17,713.64</b>	<b>17,961.01</b>
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	6.54	6.54
	(c) Trade Receivables	1.55	0.93
	(d) Cash and Cash Equivalents	3.28	5.16
	(e) Short-term Loans and Advances	63.89	63.61
	(f) Other Current Assets	-	-
	<b>Sub-total- Current Assets</b>	<b>75.26</b>	<b>76.24</b>
	<b>TOTAL ASSETS</b>	<b>17,788.90</b>	<b>18,037.25</b>

Place: Hyderabad  
Date: 14.08.2017



For and on behalf of the Board of Directors

*[Signature]*  
Dr K Koteswara Rao  
Chairman & Managing Director




**Annexure IV to Clause 41**  
**Reporting of Segment wise Revenue, Results and Capital Employed along with the Quarterly results**

(Rs. In Lakhs)

S.No	PARTICULARS	Quarter Ended 30.06.2017 (Unaudited) Rs.	Quarter Ended 31.03.2017 (Audited) Rs.	Quarter Ended 30.06.2016 (Unaudited) Rs.	Previous year Ended 31.03.2017 (Audited) Rs.
1	<b>SEGMENT REVENUE</b>				
	a)Segment -A Diagnostic Services	-	-	2.15	6.91
	b)Segment -B Agri Division	-	-	-	-
	c) Segment-C Bulk Drugs Trading	-	-	-	-
	d)Segment-D CRO Services	-	8.66	-	21.16
	e) Segment-E API-DHA	-	-	-	-
	f) Segment-F Others	0.54	0.18	1.76	4.42
	Total:	0.54	8.84	3.91	32.49
	Less: Inter Segment Revenue	-	-	-	-
	<b>Net Sales/Income From Operation</b>	<b>0.54</b>	<b>8.84</b>	<b>3.91</b>	<b>32.49</b>
2	<b>SEGMENT RESULTS</b>				
	(Profit /Loss Before Tax & Interst from each Segment)				
	a)Segment -A Diagnostic services	-	-	0.06	0.72
	b)Segment -B Agri Division	-	-	-	-
	c) Segment-C Bulk Drugs Trading	-	-	-	-
	d)Segment-D CRO Services	-	-	-	-
	e) Segment-E API-DHA	-	-	-	-
	f) Segment-F Other Unallocated	-260.37	-442.86	-524.46	-2,007.06
	g) R & D Expenses	-	-0.00	-0.01	-0.35
	<b>Total Segmental Result</b>	<b>-260.37</b>	<b>-442.86</b>	<b>-524.41</b>	<b>-2,006.70</b>
	Other Income	-	43.98	-	43.98
	<b>Total</b>	<b>-260.37</b>	<b>-398.88</b>	<b>-524.41</b>	<b>-1,962.72</b>
	Less: Interest & Finance Charges	0.00	0.00	0.02	0.08
	Less:Unallocable expenses	-	-	-	-
	Exceptional items-forex fluctuation( gain)/Loss	-	-	-	-
	<b>Total Profit/Loss Before Tax</b>	<b>-260.38</b>	<b>-398.88</b>	<b>-524.43</b>	<b>-1,962.80</b>
3	<b>CAPITAL EMPLOYED</b>				
	a)Segment - A Diagnostic services	324.83	324.83	324.83	324.83
	b)Segment - B Agri Division	24,090.93	24,090.93	24,090.93	24,090.93
	c) Segment-C Bulk Drugs	-	-	-	-
	<b>Total</b>	<b>24,415.76</b>	<b>24,415.76</b>	<b>24,415.76</b>	<b>24,415.76</b>

Place: Hyderabad  
Date: 14.08.2017



**For TRANSGENE BIOTEK LTD.**  
  
**Managing Director**

**TRANSGENE BIOTEK LIMITED**  
**AUDITED STANDALONE BALANCE SHEET AS AT 30TH JUNE 2017**  
(All amounts in Indian rupees, except share data and where otherwise stated)

Particulars	Note	As at 30th June 2017	As at 31st Mar 2017
<b>EQUITY AND LIABILITIES</b>			
<b>Shareholder's Funds</b>			
Share Capital	1	757,700,000	757,700,000
Reserves and Surplus	2	-368,508,605	(342,470,669)
<b>Non-Current Liabilities</b>			
Long-term borrowings	3	63,383,618	63,383,618
Long term provisions	4	1,208,786,442	1,208,786,442
<b>Current Liabilities</b>			
Short-term borrowings	5	90,862,476	91,672,352
Trade payables	6	5,445,147	5,596,522
Other current liabilities	7	21,220,710	19,056,753
<b>Total Equity and Liabilities</b>		<b>1,778,889,788</b>	<b>1,803,725,018</b>
<b>ASSETS</b>			
<b>Non-current assets</b>			
Fixed assets			
(i) Tangible assets		30,890,984	31,384,706
(ii) Intangible assets		556,009,061	580,252,138
Capital work-in-progress		2,890,306	2,890,306
Non-current investments	8	922,009,728	922,009,728
Long term loans and advances	9	242,087,403	242,087,403
Other non-current assets	10	17,476,633	17,476,633
<b>Current assets</b>			
Inventories	11	654,043	654,043
Trade receivables	12	154,743	92,643
Cash and cash equivalents	13	327,627	516,143
Short-term loans and advances	14	6,389,259	6,361,276
<b>Total Assets</b>		<b>1,778,889,788</b>	<b>1,803,725,018</b>

Note: The notes referred to above are an integral part of the Balance Sheet.

As per our report attached  
For Gopal & Rajan  
Chartered Accountants  
Firm Registration No.000953S

K. Goutham Subbaiah  
Partner  
Membership No:203237

Place: Hyderabad  
Date: 14.08.2017



For and on behalf of the board of Directors  
**Transgene Biotech limited**

  
Dr. K. Koteswara Rao  
Managing Director





**LIMITED REVIEW REPORT**

To,  
The Board of Directors  
M/s Transgene Biotek Limited  
Hyderabad

1. We have reviewed the accompanying statements of unaudited financial result of **M/s Transgene Biotek Limited** for the quarter ended **30<sup>th</sup> June, 2017**. The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, '*Engagements to Review Financial Statements*' issued by the Institute of Chartered accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Financial Statements are free of Material Misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Un-audited Financial results for the **Quarter ended 30<sup>th</sup> June, 2017** prepared in accordance with the applicable Accounting Standards and other recognized accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirement) Regulations, 2015 including the manner in which is to be disclosed, or that it contains any material misstatement.

For **GOPAL & RAJAN**  
CHARTERED ACCOUNTANTS

FR No. 0009535

K.GOUTHAM SUBBAIAH

M.NO. 203237

PARTNER

Place: Hyderabad.

Date: 14<sup>th</sup> August 2017



August 14, 2017

The General Manager  
Department of Corporate Services - CRD  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

Dear Sir,

**Subject: Outcome of Board Meeting.**

This has reference to our letter dated 28<sup>th</sup> July, 2017.

At the meeting of the Board of Directors of the company held on 14<sup>th</sup> August 2017 the following decisions were taken:

- 1) The unaudited financial results for the quarter ended 30<sup>th</sup> June 2017 enclosed.
- 2) It was decided to hold the 27<sup>th</sup> Annual General Meeting on Friday the 29<sup>th</sup> September 2017.
- 3) The Register of Members and Share Transfer Books of the Company will remain closed from Wednesday the 27<sup>th</sup> September 2017 to Friday the 29<sup>th</sup> September, 2017 (both days inclusive).

This is for your information and records.

Yours Sincerely  
For TRANSGENE BIOTEK LIMITED

K KOTESWARA RAO  
CHAIRMAN & MANAGING DIRECTOR

Encls: as above